Biologics - KoreaPlus-Lifes

Alteogen’s Hybrozyme: K-Bio Policy Driving Global Reach

April 23, 2026 by 도경(DOKYUNG)

alteogen k bio global strategy

South Korea’s policies boost Alteogen’s global market expansion and shape the Korean biotech trade strategy for advanced biologics.

Samsung Biologics Stock: Global CDMO Investment Outlook

April 22, 2026 by 도경(DOKYUNG)

samsung biologics cdmo outlook

Deep dive into Samsung Biologics stock analysis. Explore its earnings, valuation, and strategic position in the booming global biologics manufacturing market.

Alteogen’s Hybrozyme: Korean Subcutaneous Drug Delivery Tech Explained

April 21, 2026 by 도경(DOKYUNG)

alteogen hybrozyme drug innovation

Unpacking Alteogen’s Hybrozyme, a Korean subcutaneous drug delivery innovation transforming biologics formulation for global patient convenience.

3 Korean Technologies Already Powering AI Data Centers
by 도경(DOKYUNG)
May 7, 2026
Discover how Korean companies like Samsung Foundry and LG Energy Solution are quietly building the foundational hardware and sustainable energy systems for glob
How Naver Cloud Is Optimizing AI Data Center Efficiency
by 도경(DOKYUNG)
May 7, 2026
Naver Cloud is quietly optimizing AI data center efficiency, pioneering hyper-efficient designs in Korea for sustainable AI infrastructure.
Hanwha Aerospace vs LIG Nex1: Who Leads K-Defense Exports?
by 도경(DOKYUNG)
May 6, 2026
Analyzing Hanwha Aerospace and LIG Nex1's distinct strategies in the global K-Defense market for investors eyeing South Korea's growing defense footprint.
Inside CJ ENM: The Architect of K-Culture’s Global Rise
by 도경(DOKYUNG)
May 6, 2026
CJ ENM's global content strategy has driven the worldwide expansion of K-culture. This analysis explores their approach to Korean entertainment industry growth.
K-AI Chips Explained: How Rebellions Redefines AI Processing
by 도경(DOKYUNG)
May 5, 2026
Rebellions AI processor technology is redefining global AI hardware innovation. Explore how Korean AI chip startups are challenging established players.